This year's drug ads? Forget about 'em

If you ask viewers, this year's drug advertising lacks oomph. A ranking of the most-recalled DTC ads shows that consumers are having a harder time remembering them than they did last year. Some of 2007's most striking ads are either absent from the airwaves now or severely curtailed, including the food-or-family Vytorin pitch, Rozerem's beaver-and-Abe Lincoln extravaganza, Nasonex's buzzing bee and Lipitor's Robert Jarvik campaign. What's left, according to Nielsen and AdWeek, are a bunch of commercials whose level of recall would never have put them in the top 10 last year.

The culprit? Controversy, for one thing; money, for another. Takeda cut spending on Rozerem ads by 77 percent as the drug struggled to gain market share. Vytorin ran into controversy when a study showed that the Zocor-and-Zetia combo was no better at keeping arteries open than Zocor alone, and Congressional pressure led Merck/Schering-Plough to pull the friends-and-family ad altogether. The Nasonex bee drew criticism for its potentially distracting behavior during the ad's safety messages. And Pfizer pulled the Lipitor campaign after Congress hammered Jarvik for repping a heart drug when he's not a practicing doctor.

The most recalled ads so far this year include spots for Pfizer's Lyrica and Warner Chilcott's Loestrin 24Fe, which don't have a long-established presence on the airwaves. And Nielsen says the current crop just isn't as creative as the old. That's a problem that could worsen, the ratings firm postulates, as controversy causes companies to approach DTC advertising more cautiously and conservatively.

- read the AdWeek article

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.